AMRX

NEUTRALProduct

Amneal Pharmaceuticals, Inc.

2026-09-21

Price

$20.16

+7.75%

This is the 2026-09-21 snapshot — the signals and analysis for AMRX as of this single trading day.

View full AMRX research hub →

Score9.5Priority

Signals3/8 DNA2/13 Act · 2/4 Risk

SentimentNEUTRALScore: 9

Volume2.5xvs 20d avg

Analysis

Amneal Pharmaceuticals (AMRX) is breaking out due to the FDA approval and immediate launch of its generic lanreotide injection, targeting a reference drug market that generated $983 million in annual U.S. sales. This massive structural catalyst triggered a Barclays upgrade to Overweight, perfectly aligning with the stock's BREAKOUT and PERFECT_STACK technical signals. The urgent 2.5x volume spike confirms institutional accumulation rather than retail noise. Supported by a definitive RISK_ON macro regime that aggressively rewards high-beta risk-taking, this setup represents High-Conviction Price Discovery with strong relative leadership.

Fired Signals

GOLDEN CROSSMARKET LEADERPERFECT STACKQUIET ACCUMULATIONBREAKOUTWEAK FINISHDISTRIBUTION

Key Takeaways

Actionable Thesis: FDA approval for generic lanreotide [1.1.2] and a Barclays upgrade provide a structural catalyst, driving High-Conviction Price Discovery.
Key Risk: Immediate profit-taking at the new 52-week high given the stock's elevated 48.6% annualized volatility.
What to Watch: The $16.65 support level (recent 20-day closing low) to maintain the bullish technical structure.

← Back to 2026-09-21 View Full AMRX History →Yahoo Finance &nearr;